Cargando…

17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States

BACKGROUND: Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥ 50 years of age (YOA). The vaccine is administered in a two-dose sequence with a 2- to 6-month interval; however, the Center for Disease Control & P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patterson, Brandon J, Chen, Chi-Chang, McGuiness, Catherine B, Glasser, Lisa I, Sun, Kainan, Buck, Philip O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776021/ http://dx.doi.org/10.1093/ofid/ofaa439.062

Ejemplares similares

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
por: Patterson, Brandon J., et al.
Publicado: (2021)

Estimated incidence of pertussis in people aged <50 years in the United States
por: Chen, Chi-Chang, et al.
Publicado: (2016)

07. Recombinant Zoster Vaccine (RZV) Second-Dose Completion in Adults Age 50‒64 Years in the United States
por: Leung, Jessica, et al.
Publicado: (2021)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

The challenges of contemporary wound care
por: McGuiness, Bill
Publicado: (2011)

The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study
por: McGuiness, Catherine Balderston, et al.
Publicado: (2013)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Thumbs Up! A Novel Use of the Acutrak Screw Fixation System for the Management of Triphalangeal Thumb
por: Ahmad, Z., et al.
Publicado: (2010)

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis
por: Poirrier, Jean-Etienne, et al.
Publicado: (2022)

Results of a client satisfaction questionnaire in a NHS psychotherapy department
por: Ogston, Elizabeth, et al.
Publicado: (2021)

Respiratory Syncytial Virus Surveillance in the United States, 2007–2012: Results from a National Surveillance System
por: McGuiness, Catherine Balderston, et al.
Publicado: (2014)

Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database
por: Pandya, Bhavik J., et al.
Publicado: (2020)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

Magnetic properties of ball-milled SrFe(12)O(19) particles consolidated by Spark-Plasma Sintering
por: Stingaciu, Marian, et al.
Publicado: (2015)

The Role of Gibberellins and Brassinosteroids in Nodulation and Arbuscular Mycorrhizal Associations
por: McGuiness, Peter N., et al.
Publicado: (2019)

A comparison of the uniaxial deformation of copper and nickel (1 1 19) surfaces: a molecular dynamics study
por: Pukšič, Nuša, et al.
Publicado: (2017)

Effect of Rare Earth Elements on the Morphology of Eutectic Carbides in AISI D2 Tool Steels: Experimental and Modelling Approaches
por: Zelič, Klemen, et al.
Publicado: (2018)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

2767. Variation in Incidence of Pediatric Herpes Zoster by First- and Second-Dose Varicella Vaccine Formulations
por: Weinmann, Sheila, et al.
Publicado: (2019)

The Experience of Being a Guide Dog Puppy Raiser Volunteer: A Longitudinal Qualitative Collective Case Study
por: Chur-Hansen, Anna, et al.
Publicado: (2014)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Uveitis reactivation following recombinant zoster vaccination
por: Richards, Paige J., et al.
Publicado: (2021)

Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis
por: Almony, Arghavan, et al.
Publicado: (2021)

Probabilistic Linkage of Randomized Controlled Trial Data to Administrative Claims: A Case Study of Patients from Baricitinib Clinical Trials
por: McGuiness, Catherine B., et al.
Publicado: (2021)

Emerging Socioeconomic Disparities in COVID-19 Vaccine Second-Dose Completion Rates in the United States
por: Gertz, Autumn, et al.
Publicado: (2022)

Recombinant zoster vaccine (Shingrix(®)): a new option for the prevention of herpes zoster and postherpetic neuralgia
por: Singh, Grisuna, et al.
Publicado: (2020)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database
por: Pandya, Bhavik J., et al.
Publicado: (2019)

Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records
por: Armstrong, April W., et al.
Publicado: (2021)

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019)

Surface and Bulk Carbide Transformations in High-Speed Steel
por: Godec, M., et al.
Publicado: (2015)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Recombinant varicella zoster virus glycoprotein E antigen vaccine for prevention of herpes zoster and postherpetic neuralgia
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bo0p29iqvh56qfb6qob48cuak4